SG11202006770PA - Therapies and methods to treat tlr2-mediated diseases and disorders - Google Patents
Therapies and methods to treat tlr2-mediated diseases and disordersInfo
- Publication number
- SG11202006770PA SG11202006770PA SG11202006770PA SG11202006770PA SG11202006770PA SG 11202006770P A SG11202006770P A SG 11202006770PA SG 11202006770P A SG11202006770P A SG 11202006770PA SG 11202006770P A SG11202006770P A SG 11202006770PA SG 11202006770P A SG11202006770P A SG 11202006770PA
- Authority
- SG
- Singapore
- Prior art keywords
- tlr2
- therapies
- disorders
- treat
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623276P | 2018-01-29 | 2018-01-29 | |
| PCT/US2019/015723 WO2019148204A1 (en) | 2018-01-29 | 2019-01-29 | Therapies and methods to treat tlr2-mediated diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006770PA true SG11202006770PA (en) | 2020-08-28 |
Family
ID=67395065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006770PA SG11202006770PA (en) | 2018-01-29 | 2019-01-29 | Therapies and methods to treat tlr2-mediated diseases and disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11530259B2 (pt) |
| EP (1) | EP3746478A4 (pt) |
| JP (1) | JP7445977B2 (pt) |
| KR (1) | KR20200116104A (pt) |
| CN (1) | CN111868084B (pt) |
| AU (1) | AU2019213045B2 (pt) |
| BR (1) | BR112020015121A2 (pt) |
| CA (1) | CA3089709A1 (pt) |
| IL (1) | IL276042A (pt) |
| SG (1) | SG11202006770PA (pt) |
| WO (1) | WO2019148204A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024004291A (es) * | 2021-10-06 | 2024-06-28 | Iltoo Pharma | Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005044854A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| GEP20104991B (en) * | 2003-11-07 | 2010-05-25 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| IE20090514A1 (en) | 2009-07-06 | 2011-02-16 | Opsona Therapeutics Ltd | Humanised antibodies and uses therof |
| WO2011031460A2 (en) * | 2009-08-25 | 2011-03-17 | The Regents Of The University Of California | Novel anti-inflammatory peptides that bind oxidized phospholipids |
| WO2011160845A2 (en) * | 2010-06-24 | 2011-12-29 | Medirista Biotechnologies Ab | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| AR084210A1 (es) * | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| EP2906596B1 (en) * | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| WO2014131034A2 (en) * | 2013-02-25 | 2014-08-28 | The Regents Of The University Of California | Antibodies to oxidized phospholipids |
| US9629801B2 (en) * | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| RU2577228C2 (ru) | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| KR101771784B1 (ko) * | 2015-02-17 | 2017-08-28 | 중앙대학교 산학협력단 | Ｔｌｒ２ 신호전달계 관련 질병의 예방 및 치료용 약학 조성물 |
-
2019
- 2019-01-29 BR BR112020015121-1A patent/BR112020015121A2/pt unknown
- 2019-01-29 AU AU2019213045A patent/AU2019213045B2/en active Active
- 2019-01-29 WO PCT/US2019/015723 patent/WO2019148204A1/en active Application Filing
- 2019-01-29 CA CA3089709A patent/CA3089709A1/en active Pending
- 2019-01-29 CN CN201980020109.2A patent/CN111868084B/zh active Active
- 2019-01-29 SG SG11202006770PA patent/SG11202006770PA/en unknown
- 2019-01-29 KR KR1020207023171A patent/KR20200116104A/ko unknown
- 2019-01-29 EP EP19744139.7A patent/EP3746478A4/en active Pending
- 2019-01-29 JP JP2020540729A patent/JP7445977B2/ja active Active
- 2019-01-29 US US16/965,271 patent/US11530259B2/en active Active
-
2020
- 2020-07-14 IL IL276042A patent/IL276042A/en unknown
-
2022
- 2022-10-20 US US18/048,386 patent/US20230357374A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020015121A2 (pt) | 2021-01-05 |
| US20210155679A1 (en) | 2021-05-27 |
| CA3089709A1 (en) | 2019-08-01 |
| AU2019213045A1 (en) | 2020-08-06 |
| JP7445977B2 (ja) | 2024-03-08 |
| EP3746478A1 (en) | 2020-12-09 |
| KR20200116104A (ko) | 2020-10-08 |
| WO2019148204A1 (en) | 2019-08-01 |
| US11530259B2 (en) | 2022-12-20 |
| US20230357374A1 (en) | 2023-11-09 |
| AU2019213045B2 (en) | 2023-08-10 |
| IL276042A (en) | 2020-08-31 |
| JP2021512859A (ja) | 2021-05-20 |
| CN111868084A (zh) | 2020-10-30 |
| RU2020125162A (ru) | 2022-03-02 |
| EP3746478A4 (en) | 2022-01-19 |
| CN111868084B (zh) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246712A1 (zh) | 神經刺激治療疾病及病症 | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| ZA201602839B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL269174A (en) | Methods for treating binding-mediated diseases or disorders | |
| EP3526319A4 (en) | METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM | |
| IL287823A (en) | Anti-cd40l antibodies and methods for treating diseases or disorders related to cd40l | |
| PT3377637T (pt) | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| EP2986306A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| EP3160493A4 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| HUE059752T2 (hu) | A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek | |
| EP3507371A4 (en) | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | |
| HK1226308A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
| IL281736A (en) | Methods for treating myeloproliferative diseases | |
| IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
| HK1257583A1 (zh) | 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途 | |
| EP3341012A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| ZA201901090B (en) | Therapeutic combinations to treat red blood cell disorders | |
| HK1245671A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
| IL275913A (en) | Methods and combined treatment for cancer treatment | |
| IL276042A (en) | Treatments and methods for the treatment of tlr2-mediated diseases and disorders | |
| HK1219654A1 (zh) | 用於治療眼科疾病和病症的方法 | |
| IL281589A (en) | Methods for treating myeloproliferative diseases | |
| SG11202105279SA (en) | Methods of treating myeloproliferative disorders | |
| EP3523433C0 (en) | AGENTS AND METHODS FOR TREATING INFLAMMATORY DISEASES |